Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.39 |
| ▸ | NPC1 | O15118 | 2/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | USP30 | Q70CQ3 | 5/20 | 0.35 |
| ▸ | UCHL1 | P09936 | 3/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | RAB9A | P51151 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | PREP | P48147 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13103213 | 0.83 | UCHL1 (0.38) | HSD17B10SMN1; SMN2UCHL1 | |
| SCHEMBL30700635 | 0.83 | NR1H2 (0.42) | HSD17B10NPC1SMN1; SMN2USP30UCHL1 | |
| SCHEMBL14343539 | 0.82 | HSD17B10 (0.49) | HSD17B10NPC1SMN1; SMN2UCHL1LMNA | |
| SCHEMBL1272124 | 0.82 | HSD17B10 (0.43) | HSD17B10NPC1SMN1; SMN2UCHL1LMNA | |
| SCHEMBL1272381 | 0.81 | HSD17B10 (0.42) | HSD17B10NPC1SMN1; SMN2UCHL1LMNA | |
| SCHEMBL1271995 | 0.81 | HSD17B10 (0.42) | HSD17B10NPC1SMN1; SMN2UCHL1LMNA | |
| SCHEMBL25395953 | 0.81 | HSD17B10 (0.53) | HSD17B10NPC1SMN1; SMN2USP30UCHL1 | |
| SCHEMBL903492 | 0.81 | HSD17B10 (0.53) | HSD17B10NPC1SMN1; SMN2USP30UCHL1 | |
| SCHEMBL1584759 | 0.81 | HSD17B10 (0.53) | HSD17B10NPC1SMN1; SMN2USP30UCHL1 | |
| SCHEMBL1256351 | 0.81 | HSD17B10 (0.53) | HSD17B10NPC1SMN1; SMN2USP30UCHL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110034469-A1 | Heterocyclic Compound | BIRC5, XIAP, BIRC2 | HSD17B10 3459/4885NPC1 1601/4885SMN1; SMN2 672/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.